ASKA Pharmaceutical Co.,Ltd.

Investor Relations

Financial Highlights

Summary of Consolidated Income Statement

(million yen)
  FY2013 FY2014 FY2015 FY2016 FY2017
Net sales 39,501 42,907 43,215 48,527 48,944
Operating Income 716 1,425 1,166 1,793 2,824
Profit Attributable to Owners of Parent 495 1,193 701 2,944 2,388
R&D expenses 4,144 4,025 4,174 4,970 4,055
Return on equity (ROE) (%) 1.5 3.4 1.9 7.8 5.8

Annual Report

2017

ASUKA Report Download
"ASKA REPORT"
Download

Press Release

Information Lists